Disclosure Form: Christopher R. Snell

First Page		Document Content
Antivirals Biopharmaceuticals Companies listed on the New York Stock Exchange Hemispherx Biopharma Rintatolimod Encephalomyelitis Myelitis Myalgia Chronic fatigue syndrome treatment Health Neurological disorders Syndromes		Disclosure Form: Christopher R. Snell Add to Reading List Source URL: www.fda.gov Download Document from Source Website File Size: 70,22 KB Share Document on Facebook

	Invest in ME conference – London - May 2011 Rosamund Vallings I was privileged to attend the Invest in ME conference on 20 th May in London. The day before there were several events which helped set the scene leading u DocID: 15bhX - View Document
	Cardiac Toxicity in Chronic Fatigue Syndrome: Results from a Randomized 40-Week Multicenter Double-blind Placebo Control Trial of Rintatolimod Bruce C. Stouch, Ph.D1 DocID: NitN - View Document
	Date: To: CC: May 12, 2013 Secretary Sebelius, Dr. Howard Koh, Dr. Thomas Frieden, and Dr. Francis Collins DocID: N515 - View Document
	FDA Public Workshop Development of Safe and Effective Drug Therapies for CFS and ME Speaker, Panelist and Moderator Disclosure Form April 25 and 26, 2013 Dear Speaker, Panelist or Moderator: Please complete this form reg DocID: HI0B - View Document
	CHRONIC FATIGUE SYNDROME (CFS)/ MYALGIC ENCEPHALOMYELITIS (ME) FM-CFS Canada CFS/ME FOR PHARMACISTS Janice Sumpton, RPh, BSc.Phm DocID: EUFL - View Document